Risk-to-Benefit Relationship of Contralateral Prophylactic Mastectomy: The Argument for Bilateral Mastectomies with Immediate Reconstruction.
Blood Component Transfusion
/ statistics & numerical data
Breast Neoplasms
/ prevention & control
Carcinoma, Ductal, Breast
/ surgery
Female
Humans
Intraoperative Care
/ statistics & numerical data
Mammaplasty
/ methods
Mastectomy
/ methods
Middle Aged
Patient Readmission
/ statistics & numerical data
Postoperative Complications
/ etiology
Reoperation
/ statistics & numerical data
Retrospective Studies
Risk Factors
Surgical Flaps
/ statistics & numerical data
Treatment Outcome
Journal
Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
30
10
2019
Statut:
ppublish
Résumé
The increasing trend of women with unilateral breast cancer to electively undergo contralateral prophylactic mastectomy in addition to treatment of the index breast has been controversial. The authors set out to better frame the risks and benefits of contralateral prophylactic mastectomy in the treatment of unilateral breast cancer by evaluating outcomes of a large, consecutive cohort of patients. An institutional review board-approved review of a single-surgeon (N.T.) experience (2013 to 2018) was conducted of all consecutive patients with unilateral breast cancer treated with mastectomy and immediate reconstruction. Patient characteristics, surgical pathologic results, and 30-day complications were assessed. Outcomes of patients with unilateral cancer who underwent unilateral mastectomy versus bilateral mastectomy (with one breast being contralateral prophylactic mastectomy) were compared. Logistic regression models evaluated various risk factors for potential associations with positive pathologic findings in the contralateral prophylactic mastectomy specimen and/or postoperative complications. Of 244 patients, 68 (27.9 percent) underwent unilateral mastectomy and 176 (72.1 percent) underwent contralateral prophylactic mastectomy. Surgical pathologic results of the prophylactic breast revealed occult ductal carcinoma in situ or invasive cancer in 13 patients (7.3 percent) and lobular carcinoma in situ in eight patients (4.6 percent). Incidence of complications was similar between groups [unilateral mastectomy, 19.12 percent (n = 13); contralateral prophylactic mastectomy, 13.07 percent (n = 23); p = 0.234]. Immediate reconstruction for unilateral mastectomy and contralateral prophylactic mastectomy have similar complication risk profiles, among patients as a whole and between individual breasts. These findings contribute to our understanding of the clinical impact prophylactic mastectomy and reconstruction may have on optimizing the counseling among extirpative surgeons, reconstructive surgeons, and patients. Therapeutic, III.
Sections du résumé
BACKGROUND
The increasing trend of women with unilateral breast cancer to electively undergo contralateral prophylactic mastectomy in addition to treatment of the index breast has been controversial. The authors set out to better frame the risks and benefits of contralateral prophylactic mastectomy in the treatment of unilateral breast cancer by evaluating outcomes of a large, consecutive cohort of patients.
METHODS
An institutional review board-approved review of a single-surgeon (N.T.) experience (2013 to 2018) was conducted of all consecutive patients with unilateral breast cancer treated with mastectomy and immediate reconstruction. Patient characteristics, surgical pathologic results, and 30-day complications were assessed. Outcomes of patients with unilateral cancer who underwent unilateral mastectomy versus bilateral mastectomy (with one breast being contralateral prophylactic mastectomy) were compared. Logistic regression models evaluated various risk factors for potential associations with positive pathologic findings in the contralateral prophylactic mastectomy specimen and/or postoperative complications.
RESULTS
Of 244 patients, 68 (27.9 percent) underwent unilateral mastectomy and 176 (72.1 percent) underwent contralateral prophylactic mastectomy. Surgical pathologic results of the prophylactic breast revealed occult ductal carcinoma in situ or invasive cancer in 13 patients (7.3 percent) and lobular carcinoma in situ in eight patients (4.6 percent). Incidence of complications was similar between groups [unilateral mastectomy, 19.12 percent (n = 13); contralateral prophylactic mastectomy, 13.07 percent (n = 23); p = 0.234].
CONCLUSIONS
Immediate reconstruction for unilateral mastectomy and contralateral prophylactic mastectomy have similar complication risk profiles, among patients as a whole and between individual breasts. These findings contribute to our understanding of the clinical impact prophylactic mastectomy and reconstruction may have on optimizing the counseling among extirpative surgeons, reconstructive surgeons, and patients.
CLINICAL QUESTION/LEVEL OF EVIDENCE
Therapeutic, III.
Identifiants
pubmed: 31246789
doi: 10.1097/PRS.0000000000005690
pii: 00006534-201907000-00001
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Commentaires et corrections
Type : CommentIn
Références
Stucky CC, Gray RJ, Wasif N, Dueck AC, Pockaj BA. Increase in contralateral prophylactic mastectomy: Echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol. 2010;17(Suppl 3):330–337.
Habermann EB, Abbott A, Parsons HM, Virnig BA, Al-Refaie WB, Tuttle TM. Are mastectomy rates really increasing in the United States? J Clin Oncol. 2010;28:3437–3441.
Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in a population-based sample of patients with early-stage breast cancer. JAMA Surg. 2017;152:274–282.
Katz SJ, Hawley ST, Hamilton AS, et al. Surgeon influence on variation in receipt of contralateral prophylactic mastectomy for women with breast cancer. JAMA Surg. 2018;153:29–36.
Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol. 2007;25:5203–5209.
Hawley ST, Jagsi R, Morrow M, et al. Social and clinical determinants of contralateral prophylactic mastectomy. JAMA Surg. 2014;149:582–589.
Cemal Y, Albornoz CR, Disa JJ, et al. A paradigm shift in U.S. breast reconstruction: Part 2. The influence of changing mastectomy patterns on reconstructive rate and method. Plast Reconstr Surg. 2013;131:320e–326e.
Osman F, Saleh F, Jackson TD, Corrigan MA, Cil T. Increased postoperative complications in bilateral mastectomy patients compared to unilateral mastectomy: An analysis of the NSQIP database. Ann Surg Oncol. 2013;20:3212–3217.
Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila.) 2010;3:1026–1034.
Hislop TG, Elwood JM, Coldman AJ, Spinelli JJ, Worth AJ, Ellison LG. Second primary cancers of the breast: Incidence and risk factors. Br J Cancer 1984;49:79–85.
Yeatman TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE. Bilaterality and recurrence rates for lobular breast cancer: Considerations for treatment. Ann Surg Oncol. 1997;4:198–202.
McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938–3943.
Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: A prospective study of disease incidence. Br J Surg. 1984;71:711–714.
Schell SR, Montague ED, Spanos WJ Jr, Tapley ND, Fletcher GH, Oswald MJ. Bilateral breast cancer in patients with initial stage I and II disease. Cancer 1982;50:1191–1194.
Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project. J Clin Oncol. 2005;23:4275–4286.
Crosby MA, Garvey PB, Selber JC, et al. Reconstructive outcomes in patients undergoing contralateral prophylactic mastectomy. Plast Reconstr Surg. 2011;128:1025–1033.
Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: Are we approaching an answer? Ann Surg Oncol. 2009;16:3380–3387.
Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol. 2010;7:708–717.
Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27:5887–5892.
Buchanan PJ, Abdulghani M, Waljee JF, et al. An analysis of the decisions made for contralateral prophylactic mastectomy and breast reconstruction. Plast Reconstr Surg. 2016;138:29–40.
Rosenberg SM, Tracy MS, Meyer ME, et al. Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: A cross-sectional survey. Ann Intern Med. 2013;159:373–381.
Mattos D, Gfrerer L, Reish RG, et al. Lifetime costs of prophylactic mastectomies and reconstruction versus surveillance. Plast Reconstr Surg. 2015;136:730e–740e.
Zendejas B, Moriarty JP, O’Byrne J, Degnim AC, Farley DR, Boughey JC. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29:2993–3000.
Agarwal S, Kidwell KM, Kraft CT, et al. Defining the relationship between patient decisions to undergo breast reconstruction and contralateral prophylactic mastectomy. Plast Reconstr Surg. 2015;135:661–670.
Katz SJ, Morrow M. Contralateral prophylactic mastectomy for breast cancer: Addressing peace of mind. JAMA 2013;310:793–794.
Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: A decision analysis. J Natl Cancer Inst. 2014;106:pii: dju160.
Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. 2014;21:3231–3239.
Yao K, Sisco M, Bedrosian I. Contralateral prophylactic mastectomy: Current perspectives. Int J Womens Health 2016;8:213–223.
Yao K, Winchester DJ, Czechura T, Huo D. Contralateral prophylactic mastectomy and survival: Report from the National Cancer Data Base, 1998-2002. Breast Cancer Res Treat. 2013;142:465–476.
Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer. Ann Surg. 2017;265:581–589.
Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 2014;312:902–914.
Eck DL, Perdikis G, Rawal B, Bagaria S, McLaughlin SA. Incremental risk associated with contralateral prophylactic mastectomy and the effect on adjuvant therapy. Ann Surg Oncol. 2014;21:3297–3303.
Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy: Predictors of significant histologic findings. Cancer 2004;101:1977–1986.
Chang EI, Chang EI, Soto-Miranda MA, et al. Evolution of bilateral free flap breast reconstruction over 10 years: Optimizing outcomes and comparison to unilateral reconstruction. Plast Reconstr Surg. 2015;135:946e–953e.
Murthy V, Chamberlain RS. Prophylactic mastectomy in patients at high risk: Is there a role for sentinel lymph node biopsy? Clin Breast Cancer 2013;13:180–187.
Nasser SM, Smith SG, Chagpar AB. The role of sentinel node biopsy in women undergoing prophylactic mastectomy. J Surg Res. 2010;164:188–192.
Deshmukh AA, Cantor SB, Crosby MA, et al. Cost of contralateral prophylactic mastectomy. Ann Surg Oncol. 2014;21:2823–2830.
Boughey JC, Schilz SR, Van Houten HK, Zhu L, Habermann EB, Lemaine V. Contralateral prophylactic mastectomy with immediate breast reconstruction increases healthcare utilization and cost. Ann Surg Oncol. 2017;24:2957–2964.
Billig JI, Duncan A, Zhong L, et al. The cost of contralateral prophylactic mastectomy in women with unilateral breast cancer. Plast Reconstr Surg. 2018;141:1094–1102.
Rosenberg SM, Sepucha K, Ruddy KJ, et al. Local therapy decision-making and contralateral prophylactic mastectomy in young women with early-stage breast cancer. Ann Surg Oncol. 2015;22:3809–3815.
Soran A, Ibrahim A, Kanbour M, et al. Decision making and factors influencing long-term satisfaction with prophylactic mastectomy in women with breast cancer. Am J Clin Oncol. 2015;38:179–183.
Albornoz CR, Matros E, Lee CN, et al. Bilateral mastectomy versus breast-conserving surgery for early-stage breast cancer: The role of breast reconstruction. Plast Reconstr Surg. 2015;135:1518–1526.
Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M. Society of Surgical Oncology: Position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol. 2007;14:2425–2427.
Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24:1350–1356.
Mattos D, Gfrerer L, Ling IT, et al. Occult histopathology and its predictors in contralateral and bilateral prophylactic mastectomies. Ann Surg Oncol. 2016;23:767–775.
Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: The significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23:7849–7856.
Lin KY, Johns FR, Gibson J, Long M, Drake DB, Moore MM. An outcome study of breast reconstruction: Presurgical identification of risk factors for complications. Ann Surg Oncol. 2001;8:586–591.
Kroll SS, Netscher DT. Complications of TRAM flap breast reconstruction in obese patients. Plast Reconstr Surg. 1989;84:886–892.
Alderman AK, Wilkins EG, Kim HM, Lowery JC. Complications in postmastectomy breast reconstruction: Two-year results of the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg. 2002;109:2265–2274.
Paige KT, Bostwick J III, Bried JT, Jones G. A comparison of morbidity from bilateral, unipedicled and unilateral, unipedicled TRAM flap breast reconstructions. Plast Reconstr Surg. 1998;101:1819–1827.
Garvey PB, Villa MT, Rozanski AT, Liu J, Robb GL, Beahm EK. The advantages of free abdominal-based flaps over implants for breast reconstruction in obese patients. Plast Reconstr Surg. 2012;130:991–1000.
Hart A, Funderburk CD, Chu CK, et al. The impact of diabetes mellitus on wound healing in breast reconstruction. Ann Plast Surg. 2017;78:260–263.